Open AccessChikungunya Vaccine Candidates: Current Landscape and Future Prospects
Author(s) -
Christin Schmidt,
Barbara S. Schnierle
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s366112
Subject(s) - alphavirus , chikungunya , virology , immune system , virus , alphavirus infection , togaviridae , vector (molecular biology) , medicine , immunology , attenuated vaccine , biology , biochemistry , virulence , gene , recombinant dna
Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.